Description
CARB‑X supports startups developing novel antibiotics, diagnostics, vaccines, and enabling technologies to combat antimicrobial resistance. The program provides substantial non‑dilutive funding, technical expertise, and commercialization support to advance products toward clinical and regulatory milestones.
Eligibility
• Antibacterial, antimicrobial, or AMR‑focused startups
• Strong scientific and technical foundation
• Preclinical through early clinical development
• Clear path toward commercialization and impact
Process
Sourcing: Open global calls and competitive selection
Evaluation: Scientific merit, unmet medical need, feasibility, impact
Engagement Model: Milestone‑driven acceleration with expert support
Capital Structure: Fully non‑dilutive grant funding
What an Applicant can Obtain
✔ $0–$15M+ in non‑dilutive grant funding
✔ Scientific, clinical, and regulatory expertise
✔ Milestone‑based development support
✔ Global visibility and credibility
✔ Access to public‑health and life‑science networks
